With more than 40 years of experience in normal human cells and best-in-class cGMP compliance, Lonza Walkersville, Inc. is the industry leader in development, manufacturing and testing services for cell-based therapeutics. Our R&D organization has a wide range of expertise in technology and media development.

Our process development scientists partner with our clients to develop client-specific custom protocols.  We meet each unique need, encompassing every aspect of the business from raw material requirements, process flow, scalability, closed systems, automated vialing, to storage and distribution.

In May 2017, we announced investments into exosome technologies for new generation life science applications. To find out more about this exciting field, read an interview of Dr. Behzad Mahdavi, VP Strategic Innovation and Alliances for Lonza:  Lonza's New Investments in Exosome Technologies Reflect Growing Industry Interest.

Alberto Santagostino recently joined us as VP,  Business Unit Head of Cell and Gene Technologies (CGT) from McKinsey and brings with him extensive experience from the biomanufacturing industry. We caught up with him in between the ESGCT conference and a visit to Lonza’s Netherland site for cell and gene therapy manufacturing. Read the interview with Alberto Santagostino.

Please contact us at celltherapy@lonza.com for further information or requests.